Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

In this study, finasteride-treated WAG/Rij rats showed a significant increase in spike-wave discharges when administered endogenous steroids THPROG and THDOC, indicating potential exacerbation of absence seizures.

Finasteride metabolism varies by age, sex, and P450 inducers, with males processing it faster.

This research describes the synthesis of 16β-chloro- and 16β-bromo-cyproterone acetate, detailing the chemical processes involved, but reports no clinical outcomes.

This study found that diagnosing non-classical 3 beta-hydroxysteroid dehydrogenase deficiency solely based on elevated serum or urinary 5-ene-steroids may not be reliable.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

This review discusses gender-linked skin differences, such as hormone metabolism and sebum production, and reports no new findings; it suggests these insights might inform male-specific dermatological treatments or cosmetic products.

This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This study found that in androgenetic alopecia, reduced stem cell factor production by dermal papilla cells may lead to decreased pigmentation in hair follicles.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

This study found that male pattern hair loss may be associated with differences in serum levels of androstenedione, cortisol, 17 beta-estradiol, and luteinizing hormone, compared to controls.

This study found that the yeast androgen screen (YAS) could detect the activity of methyltestosterone in urine for a longer period than classical GC/MS, potentially identifying long-lasting metabolites.

This review discusses the diagnostic challenges of androgen and estrogen-secreting adrenal tumors and highlights that the presence of metastases is the most reliable indicator of malignancy; it reports no new clinical findings.

This study found that women with female pattern baldness had a marked increase in the 3α,17β-androstanediol glucuronide/sex hormone binding globulin ratio and low serum sex hormone binding globulin.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.

This study found that Origanum vulgare extract improved testicular structure and function in mice against finasteride-induced damage by enhancing antioxidant defense and modulating gene expression related to apoptosis.

This study found that sulforaphane may help alleviate hair loss by increasing hair count after 18 weeks of use and enhancing the expression of a DHT-degrading enzyme in cellular models.

This case report describes hair regrowth in a 73-year-old male who had been bald for decades, which might be associated with the antiandrogenic effects of spironolactone.

This review discusses genetic and epigenetic studies of PCOS, highlighting Genome-Wide Association Studies that found genetic variants related to gonadotrophin secretion influencing PCOS susceptibility, but it reports no new findings.

This case report describes the effective use of spironolactone for hirsutism in a patient with porphyria cutanea tarda.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This review discusses the effects of estrogen on skin aging and highlights potential therapies, but reports no new clinical findings.

This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.